Literature DB >> 9756909

Identification of three major sentrinization sites in PML.

T Kamitani1, K Kito, H P Nguyen, H Wada, T Fukuda-Kamitani, E T Yeh.   

Abstract

Acute promyelocytic leukemia arises following a reciprocal chromosome translocation t(15;17), which generates PML-retinoic acid receptor alpha fusion proteins (PML-RARalpha). We have shown previously that wild type PML, but not PML-RARalpha, is covalently modified by the sentrin family of ubiquitin-like proteins (Kamitani, T., Nguyen, H. P., Kito, K., Fukuda-Kamitani, T., and Yeh, E. T. H. (1998) J. Biol. Chem. 273, 3117-3120). To understand the mechanisms underlying the differential sentrinization of PML versus PML-RARalpha, extensive mutational analysis was carried out to determine which Lys residues are sentrinized. We show that Lys65 in the RING finger domain, Lys160 in the B1 Box, and Lys490 in the nuclear localization signal contributes three major sentrinization sites. The PML mutant with Lys to Arg substitutions in all three sites is expressed normally, but cannot be sentrinized. Furthermore, the triple substitution mutant is localized predominantly to the nucleoplasm, in contrast to wild type PML, which is localized to the nuclear bodies. Thus, sentrinization of PML, in the context of the RING finger and the B1 box, regulates nuclear body formation. Furthermore, we showed that sentrinization of PML-RARalpha could be restored by overexpression of sentrin, but not by retinoic acid treatment. These studies provide novel insight into the pathobiochemistry of acute promyelocytic leukemia and the sentrinization pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756909     DOI: 10.1074/jbc.273.41.26675

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  101 in total

1.  UBC9 autosumoylation negatively regulates sumoylation of septins in Saccharomyces cerevisiae.

Authors:  Chia-Wen Ho; Hung-Ta Chen; Jaulang Hwang
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

2.  The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Authors:  Andrea Rabellino; Brandon Carter; Georgia Konstantinidou; Shwu-Yuan Wu; Alessandro Rimessi; Lauren A Byers; John V Heymach; Luc Girard; Cheng-Ming Chiang; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

3.  Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7.

Authors:  Qiming Liang; Hongying Deng; Xiaojuan Li; Xianfang Wu; Qiyi Tang; Tsung-Hsien Chang; Hongzhuang Peng; Frank J Rauscher; Keiko Ozato; Fanxiu Zhu
Journal:  J Immunol       Date:  2011-09-21       Impact factor: 5.422

4.  Resistance to rabies virus infection conferred by the PMLIV isoform.

Authors:  Danielle Blondel; Sabrina Kheddache; Xavier Lahaye; Laurent Dianoux; Mounira K Chelbi-Alix
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

5.  Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.

Authors:  Daniel Bailey; Peter O'Hare
Journal:  Biochem J       Date:  2005-12-01       Impact factor: 3.857

6.  PML regulates PER2 nuclear localization and circadian function.

Authors:  Takao Miki; Zhixiang Xu; Misty Chen-Goodspeed; Mingguang Liu; Anita Van Oort-Jansen; Michael A Rea; Zhaoyang Zhao; Cheng Chi Lee; Kun-Sang Chang
Journal:  EMBO J       Date:  2012-01-24       Impact factor: 11.598

7.  TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation.

Authors:  Yutaka Morita; Chie Kanei-Ishii; Teruaki Nomura; Shunsuke Ishii
Journal:  Mol Biol Cell       Date:  2005-09-14       Impact factor: 4.138

8.  Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.

Authors:  Y Xu; J H Ahn; M Cheng; C M apRhys; C J Chiou; J Zong; M J Matunis; G S Hayward
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  SUMO modification of Rad22, the Schizosaccharomyces pombe homologue of the recombination protein Rad52.

Authors:  J C Ho; N J Warr; H Shimizu; F Z Watts
Journal:  Nucleic Acids Res       Date:  2001-10-15       Impact factor: 16.971

10.  Dynamic movements of Ro52 cytoplasmic bodies along microtubules.

Authors:  Makoto Tanaka; Kunikazu Tanji; Motoko Niida; Tetsu Kamitani
Journal:  Histochem Cell Biol       Date:  2009-12-16       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.